INVESTMENT VIEWPOINT

Australia Analyst Discovers Key Finding in the U.S.

Kim Tracey , Investment Professional, Health Care in Australia

For T. Rowe Price investment professional Kim Tracey, pertinent insights for her Australian health services coverage can occur anywhere on the planet. On a recent research trip to the United States, Kim detected a chronic shortage of global plasma supplies at a time when plasma-based protein therapies are in high demand. The United States provides about 70% of the world’s plasma, but it has been tougher to attract plasma donors.
 

After attending trade shows and talking with major public companies and smaller private companies involved in the plasma-derived therapies industry, as well as independent collection centers and equipment suppliers, she concluded that the plasma market would remain tight for quite a while. “Hospitals were rationing the product for all patients, even for people with life threatening diseases,” she says. “It’s the kind of insight you can’t get just studying the market from your office or running spreadsheets.”


She says a challenging market can be favorable for the plasma industry in the short term, but “rationing the product is ultimately one of the worst things that can happen. Governments and other payors could dictate what patients get and how they get it, which could restrain manufacturers’ profitability. Also, if patients and prescribers don’t think they can get supply, they may try alternative products and it can be challenging to get them back.”
 

This imbalance has implications for Melbourne-based CSL Limited, a major manufacturer of plasma-derived and recombinant therapies. While rationing of plasma could adversely impact profitability, Kim is optimistic about CSL’s earnings potential near term. “Clearly, there is strong demand and the supply is restrained,” she says. “The company has pricing power in some markets. That’s incrementally positive for CSL and reaffirms our favorable near-term outlook for the company.”

The qualitative input from the field can really help in forming a view on the sustainability of a business and the management team.

Going Beyond the Numbers Reveals the Full Story

At T. Rowe Price, our investment approach is to go beyond the numbers when evaluating what companies may offer the best future potential. By getting out into the field, we gain insights and a deeper understanding of where a company or industry stands and where it could go in the future.
 

For Kim, that means spending about 20% of her time visiting companies, as well as their competitors, suppliers, and customers. On the recent U.S. trip, she visited with biotech companies that research diseases treated with plasma products.


Getting Ahead of Change 

“Firsthand research is tremendously important,” Kim says. “People tend to be more forthcoming in face-to-face meetings, and it can be easier putting all the pieces of the puzzle together. At industry events, you never know who you might meet that will have some insights into the industry or individual companies that you won’t get in the office or find out any other way. The qualitative input from the field can really help in forming a view on the sustainability of a business and the management team. Field research can also highlight important emerging trends.”
 


Important Information

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.
 

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.
 

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.
 

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.
 

Australia—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.

 

201907-903672

RELATED FUND
AUT
APIR Code ETL0328AU
Seeking high-quality Australian companies undervalued by the market.

Class S PDS

Class I PDS
View More...
Since
Inception
11.51%
Fund Size
(AUD)
$56.7m